Boxer Capital, LLC Mirati Therapeutics, Inc. Transaction History

Boxer Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $50.4 Million - $74.9 Million	1,201,440 Added 60.07%	3,201,440 $188 Million
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $37.3 Million - $52 Million	234,440 Added 13.28%	2,000,000 $343 Million
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $3.49 Million - $5.81 Million	50,000 Added 2.91%	1,765,560 $136 Million
Q1 2019 May 15, 2019	BUY	$43.65 - $78.95 $6.55 Million - $11.8 Million	150,000 Added 9.58%	1,715,560 $126 Million
Q2 2018 Aug 14, 2018	BUY	$26.05 - $52.4 $5.03 Million - $10.1 Million	193,050 Added 14.07%	1,565,560 $77.2 Million
Q4 2017 Feb 14, 2018	BUY	$12.65 - $19.0 $4.23 Million - $6.36 Million	334,516 Added 32.23%	1,372,510 $25 Million
Q3 2017 Nov 14, 2017	BUY	$4.7 - $11.7 $4.88 Million - $12.1 Million	1,037,994	1,037,994 $12.1 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Boxer Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Boxer Capital, LLC with notifications on news.